Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Core Viewpoint - Nanobiotix announced the presentation of full results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) for locally advanced or borderline resectable pancreatic cancer, highlighting the potential of its nanoparticle-based therapeutic approach in oncology [1][6]. Group 1: Study Details - The Phase 1 study was conducted by The University of Texas MD Anderson Cancer Center and will be presented by Dr. Eugene Koay at the ESTRO 2025 conference on May 4, 2025 [1][6]. - The study includes both dose escalation and dose expansion phases, focusing on patients who have undergone induction chemotherapy [6]. Group 2: Product Information - NBTXR3 is a novel oncology product made of functionalized hafnium oxide nanoparticles, administered via a one-time intratumoral injection and activated by radiotherapy [4]. - The mechanism of action is designed to induce significant tumor cell death and trigger an adaptive immune response, potentially applicable across various solid tumors treated with radiotherapy [4]. Group 3: Regulatory and Collaboration Efforts - NBTXR3 received a European CE mark in 2019 for soft tissue sarcomas and has been granted Fast Track designation by the FDA for use in locally advanced head and neck squamous cell cancers [5]. - Nanobiotix has engaged in a collaboration with MD Anderson Cancer Center to sponsor multiple studies evaluating NBTXR3 across different tumor types and therapeutic combinations [7]. Group 4: Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve treatment outcomes for cancer patients [8]. - The company was incorporated in 2003 and is headquartered in Paris, France, with additional locations including Cambridge, Massachusetts [9].